Innate Pharma SA announced that the company will host a conference call on November 5, 2026, at 2:00 p.m. CET / 8:00 a.m. ET to deliver its third-quarter 2026 business and financial update, according to a corporate release distributed via Business Wire.
Innate Pharma Schedules Q3 2026 Business Update Call
- Innate Pharma scheduled its Q3 2026 financial and business update conference call for November 5, 2026.
- Executive leadership participating in the upcoming call includes CEO Jonathan Dickinson and CFO Frédéric Lombard.
- The company continues to advance its proprietary antibody-drug conjugate pipeline alongside partnered late-stage oncology assets.
Executive Roster Set for November Update
Leadership figures slated for the upcoming call include Chief Executive Officer Jonathan Dickinson, Vice President, Chief Medical Officer Markus Jensen, and Executive Vice President, Chief Operating Officer Yannis Morel. They will be joined by Stéphanie Cornen, Vice President, Investor Relations and Communications, and Senior Vice President, Chief Financial Officer Frédéric Lombard.
Participants can access the event through official webcast registration links provided by the firm. A dial-in option is also available via the designated conference call link. The company confirmed that a replay will remain accessible on the Innate Pharma website for 90 days following the broadcast.
$IPHA 01:00 on Oct. 20 2026Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
Pipeline Focus on Clinical Assets
Headquartered in Marseille, France, Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) operates as a clinical-stage biotechnology company focused on immuno-oncology. Its proprietary pipeline highlights antibody-drug conjugates, led by IPH4502 targeting Nectin-4 in solid tumors.
In parallel, the company maintains partnerships for late-stage clinical candidates. These include lacutamab, developed alongside Sobi for cutaneous T-cell lymphomas, and monalizumab, advanced with AstraZeneca for non-small cell lung cancer.
| Asset | Indication | Partner |
|---|---|---|
| IPH4502 | Solid Tumors (ADCs) | Proprietary |
| Lacutamab | Cutaneous T-Cell Lymphomas | Sobi |
| Monalizumab | Non-Small Cell Lung Cancer | AstraZeneca |
Regulatory and Compliance Disclosures
The upcoming financial disclosure follows prior filings submitted to regulatory bodies. These include the Universal Registration Document filed with the French Financial Markets Authority and annual reports submitted to the U.S. Securities and Exchange Commission, referenced in compliance with company disclosure obligations.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
